Viral infection or reactivation in patients during treatment with dasatinib: a call for screening?
Torres
Harrys A
HA
Department of Infectious Diseases, Infection Control and Employee Health, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030-4009, USA.
Chemaly
Roy F
RF
D003586:Cytomegalovirus Infections / Q000209:etiology; D000069439:Dasatinib; D015654:Herpesvirus 6, Human / Q000502:physiology; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy*; D010322:Parvoviridae Infections / Q000209:etiology; D016732:Parvovirus B19, Human; D047428:Protein Kinase Inhibitors / Q000009:adverse effects*; D011743:Pyrimidines / Q000009:adverse effects*; D013844:Thiazoles / Q000009:adverse effects*; D014775:Virus Activation / Q000187:drug effects*
D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D013844:Thiazoles; D000069439:Dasatinib